Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Cancer Center Leads Breakthrough Clinical Trial: Cancer Vaccine For First Time Shows Promise Against Melanoma
A recent clinical trial - led by Goshen Center for Cancer Care - has yielded promising results for the future use of a cancer vaccine. One of the first studies to prove vaccines might have a medical benefit against cancer, study results found the new cancer vaccine doubled the response rate for tumor shrinkage as well as delayed the progression of cancer in patients with metastatic melanoma.
generic viagra online
Breaking The Boundaries Between Primary And Secondary Care, UK
The second wave of Integrated Care Pilots should be developed among existing promising commissioners and providers to encourage a complete restructuring of the way primary and secondary work together.
News of the day
Many U.S. Residents Test Positive For HIV Late In Illness, Few High School Students
Many people who test positive for HIV are diagnosed late in the course of their infection when treatment might be less effective, according to a report published Thursday in CDC"s Morbidity and Mortality Weekly Report, Reuters Health reports. The report looked at data on people who were diagnosed with HIV from 1996 to 2005 and found that 45 percent had developed AIDS within three years of their initial HIV diagnosis, 38.3 percent within one year and an additional 6.7 percent within the next two years (Reuters Health 6/25). R. Luke Shouse of CDC"s Division of HIV/AIDS Prevention in the National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, said, "This means that they may have unknowingly transmitted HIV. It also means that there is a time when they had HIV when they were not under appropriate medical care, so there are missed opportunities for prevention and care." A separate CDC report also published yesterday found that 22.3 percent of high school students who are sexually active and 12.9 percent of all students have been tested for HIV (Reinberg, HealthDay/KATC.com, 6/25).
Diagnostics

NIH Deepens Investment In Combination Study Of MS Drugs

The first large-scale "CombiRX" clinical trial testing the combined use of FDA-approved interferon beta-1a (Avonex®) and glatiramer acetate (Copaxone®) to treat relapsing-remitting MS has just received a $19-million renewal grant from the National Institutes of Health. This is the largest MS trial ever supported by the NIH, with a cumulative investment of more than $44 million. The long-term trial is led by principal investigator Fred Lublin, MD, (Corinne Goldsmith Dickinson Multiple Sclerosis Center at Mount Sinai School of Medicine, New York, NY). The study is now fully enrolled, with more than 1,000 participants at 67 medical centers across the United States and Canada. Dr. Lublin is a member of the National Board of Directors of the National MS Society and the Society"s National Clinical Advisory Board and the New York City Chapter Clinical Advisory Committee. Combination therapy is being compared to the use of either agent alone for 36 months. All participants are receiving at least one active medication and there is not a placebo-only treatment arm. Each of these treatments is approved by the U.S. Food and Drug Administration for the treatment of relapsing MS. A previous, smaller pilot trial of the combination therapy suggested it was safe and warranted further study. An important ancillary study to this trial, the NIH-sponsored biomarker project, is examining genetic and other biological markers at baseline and at a minimum of one additional point during the study. The hope is that these biological markers will provide a means for identifying, in the future, those patients with more aggressive disease as well as those who respond or fail to respond to therapy. Such markers would have considerable value in the management of MS. Read more about this study in its listing on clinicaltrials.gov. MS Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009